PT3778903T - Arenavírus tri-segmentados como vetores de vacinas - Google Patents

Arenavírus tri-segmentados como vetores de vacinas

Info

Publication number
PT3778903T
PT3778903T PT201844685T PT20184468T PT3778903T PT 3778903 T PT3778903 T PT 3778903T PT 201844685 T PT201844685 T PT 201844685T PT 20184468 T PT20184468 T PT 20184468T PT 3778903 T PT3778903 T PT 3778903T
Authority
PT
Portugal
Prior art keywords
tri
vaccine vectors
arenaviruses
segmented
segmented arenaviruses
Prior art date
Application number
PT201844685T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54545130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3778903(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Geneve filed Critical Univ Geneve
Publication of PT3778903T publication Critical patent/PT3778903T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10041Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10061Methods of inactivation or attenuation
    • C12N2760/10062Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/80Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT201844685T 2014-11-13 2015-11-12 Arenavírus tri-segmentados como vetores de vacinas PT3778903T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462079493P 2014-11-13 2014-11-13

Publications (1)

Publication Number Publication Date
PT3778903T true PT3778903T (pt) 2026-03-31

Family

ID=54545130

Family Applications (2)

Application Number Title Priority Date Filing Date
PT201844685T PT3778903T (pt) 2014-11-13 2015-11-12 Arenavírus tri-segmentados como vetores de vacinas
PT157949009T PT3218504T (pt) 2014-11-13 2015-11-12 Arenavírus trissegmentados como vetores de vacinas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT157949009T PT3218504T (pt) 2014-11-13 2015-11-12 Arenavírus trissegmentados como vetores de vacinas

Country Status (18)

Country Link
US (3) US10722564B2 (enExample)
EP (2) EP3778903B1 (enExample)
JP (4) JP6805139B2 (enExample)
CN (2) CN122036892A (enExample)
AU (3) AU2015345080B2 (enExample)
CA (1) CA2967720C (enExample)
CY (1) CY1123339T1 (enExample)
DK (2) DK3778903T3 (enExample)
ES (1) ES2811093T3 (enExample)
FI (1) FI3778903T3 (enExample)
HR (2) HRP20201684T1 (enExample)
HU (1) HUE051390T2 (enExample)
LT (2) LT3778903T (enExample)
PL (1) PL3218504T3 (enExample)
PT (2) PT3778903T (enExample)
RS (1) RS60937B1 (enExample)
SI (2) SI3778903T1 (enExample)
WO (1) WO2016075250A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604695T (lt) 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
CN115197965A (zh) * 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
WO2018045029A1 (en) * 2016-09-02 2018-03-08 The United States Of America, As Represented By The Secretary Of The Army Pan south american arenavirus live attenuated vaccine
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
EP3373959B1 (en) * 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
WO2018083220A2 (en) 2016-11-04 2018-05-11 Hookipa Biotech Ag Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP3606549A1 (en) * 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
CN108611310A (zh) * 2018-04-28 2018-10-02 中国药科大学 一种重组Hsp65与STEAP1186-193融合蛋白的基因工程菌的构建
CN108977434A (zh) * 2018-07-03 2018-12-11 张罗 鼻腔脱落细胞rna的提取方法
US20220226467A1 (en) * 2019-06-18 2022-07-21 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
IL298420A (en) 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
WO2022159664A1 (en) * 2021-01-22 2022-07-28 Chan Zuckerberg Biohub, Inc. Engineered multi-segmented rna viruses for large-scale combinatorial genetic screening
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
WO2022238546A1 (en) 2021-05-13 2022-11-17 Hookipa Biotech Gmbh Arenaviruses as vectors
EP4429698A1 (en) 2021-11-08 2024-09-18 Hookipa Biotech GmbH Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
CN114231562A (zh) * 2021-12-15 2022-03-25 中国科学院武汉病毒研究所 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
KR20250036855A (ko) 2022-07-12 2025-03-14 길리애드 사이언시즈, 인코포레이티드 Hiv 면역원성 폴리펩타이드 및 백신, 및 이들의 용도
CN121866044A (zh) 2023-09-15 2026-04-14 吉利德科学公司 沙粒病毒制剂、方法及其用途
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
LT2604695T (lt) * 2007-12-27 2022-12-12 Universität Zürich Replikacijos defektų turintys arenaviruso vektoriai
GB201001726D0 (en) 2010-02-03 2010-03-24 Univ St Andrews Bunyavirus vaccine
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
JP6219849B2 (ja) 2012-01-24 2017-10-25 サンフォード ヘルス 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
PL3198008T3 (pl) * 2014-09-22 2020-03-31 Regents Of The University Of Minnesota Układ wykorzystujący odwrotną genetykę wirusa pichinde i sposoby zastosowania
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
RS60937B1 (sr) 2014-11-13 2020-11-30 Univ Geneve Tri-segmentirani arenavirusi kao vektori za vakcinu
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
CN115197965A (zh) 2015-06-10 2022-10-18 霍欧奇帕生物科技有限公司 Hpv疫苗
US10849969B2 (en) 2015-10-23 2020-12-01 Institut Pasteur Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
CN117486979A (zh) 2016-05-18 2024-02-02 巴塞尔大学 作为疫苗载体的三区段pichinde病毒
WO2018083220A2 (en) 2016-11-04 2018-05-11 Hookipa Biotech Ag Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
EP3606549A1 (en) 2017-04-07 2020-02-12 Hookipa Biotech GmbH Arenavirus particles to treat solid tumors

Also Published As

Publication number Publication date
JP7796680B2 (ja) 2026-01-09
PL3218504T3 (pl) 2021-02-08
HK1244034A1 (en) 2018-07-27
JP6805139B2 (ja) 2020-12-23
PT3218504T (pt) 2020-09-24
AU2015345080B2 (en) 2022-01-27
FI3778903T3 (fi) 2026-02-24
EP3218504B1 (en) 2020-07-22
US20210145950A1 (en) 2021-05-20
SI3218504T1 (sl) 2020-11-30
EP3218504A1 (en) 2017-09-20
LT3778903T (lt) 2026-02-10
CN107223130A (zh) 2017-09-29
US10722564B2 (en) 2020-07-28
SI3778903T1 (sl) 2026-03-31
AU2022200061A1 (en) 2022-02-03
JP2021045154A (ja) 2021-03-25
RS60937B1 (sr) 2020-11-30
HUE051390T2 (hu) 2021-03-01
HRP20201684T1 (hr) 2020-12-25
AU2024259760A1 (en) 2024-11-28
CA2967720C (en) 2024-01-02
WO2016075250A1 (en) 2016-05-19
CN122036892A (zh) 2026-05-15
CA2967720A1 (en) 2016-05-19
ES2811093T3 (es) 2021-03-10
EP3778903A1 (en) 2021-02-17
DK3218504T3 (da) 2020-10-19
US20240082376A1 (en) 2024-03-14
LT3218504T (lt) 2020-09-10
EP3778903B1 (en) 2026-01-14
AU2015345080A1 (en) 2017-06-01
US20170319673A1 (en) 2017-11-09
JP2017535267A (ja) 2017-11-30
CY1123339T1 (el) 2021-12-31
JP2023036933A (ja) 2023-03-14
JP2025170342A (ja) 2025-11-18
DK3778903T3 (da) 2026-02-09
HRP20260167T1 (hr) 2026-03-27

Similar Documents

Publication Publication Date Title
FIC20240035I1 (fi) Toferseeni
LT3218504T (lt) Trijų segmentų arenavirusai kaip vakcinos vektoriai
DK3393510T5 (da) Zikavirusvaccine
DK3234128T3 (da) Sekventeringskontroller
DK3171891T3 (da) Fremgangsmåde
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (en) N-GLYCOSYLATION
ES2648672T5 (en) Improved hvt-vectored nd-ibd vaccine
CL2016002146A1 (es) Plásmidos inmunoestimuladores
BR112017013316A2 (pt) tiazolopiridinonas como herbicidas
HUE053668T2 (hu) Oltóanyag immunkompromittáltak számára
HUE047581T2 (hu) Készítmény
DE202014005655U8 (de) llluminationsvorrichtung
LT3188755T (lt) Vakcina
EP3171776C0 (de) Abbildungsanordnung
FI20145173L (fi) Esikammiojärjestely
DK3183264T3 (da) Pegyleringsfremgangsmåde
DK3191825T3 (da) Kreatininbiosensor
ES1098331Y (es) Abaco mejorado
TH1601000793A (th) สิ่งทอ
UA28615S (uk) Сірник
UA28476S (uk) Сірник
UA30041S (uk) Сірник
ES1136182Y (es) Senalizador de peldanos fotoluminiscentes
TH1601003236A (th) วัคซีนสุกร